JavaScript Required

This application requires JavaScript to function properly.

Please enable JavaScript in your browser settings and reload the page.

Ramin Hamidi

Asst Professor Term

School of Medicine

Orcid identifier0000-0001-8506-8335

Asst Professor Term
School of Medicine

ramin.hamidi@louisville.edu

SPONSORED PROJECTS

Interested and currently working on technology transfer projects with AI and pulse sequences.

Using technology developed at the University of Louisville to improve imaging diagnostic accuracy thereby leading to better healthcare.

SPONSORED PROJECTS

Showing page 1 out of 1

sort by:

Showing page 1, sponsored projects 1 to 8 of 8

sort by:

GRANT

250583 | MK-5909-003-0009 - A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Merck and Company Inc_MERCKCO6 Sep 2025 - 6 Aug 2030

GRANT

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Bicara Therapeutics Inc_BTI1 Jan 2025

GRANT

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent and in Combination in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair

Worldwide Clinical Trials Inc_WCT1 Jan 2025

GRANT

Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors

1 Jan 2025

GRANT

241001|D7630C00001 - A Phase III, Open-label, Random Study of Datopotamab Deruxtecan (Dato-DXd) in Comb With Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Comb With Pembrolizumab

AstraZeneca LP_ASTRALP11 Jun 2024

GRANT

240992|ALLO-501A-202 - A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)

PSI CRO AG1 Jan 2024

GRANT

240845|MK-2870 -A Phase 3 Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma

Merck and Company Inc_MERCKCO5 Jan 2023

GRANT

240533|ABBV-GMAB-3013 - A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to hemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE FL-2)

AbbVie Inc_ABBVI1 Jan 2023